Latest urinary retention Stories

PARKERS PRAIRIE, Minn., July 6 /PRNewswire/ -- AbbeyMoor Medical Inc., a developer and manufacturer of medical devices for the management and treatment of prostatic obstruction, announced today that it has received PMA approval from the US Food and Drug Administration (FDA) for design changes to their flagship product, The Spanner(TM) Prostatic Stent. "These changes are aimed at further improving patient comfort over the current highly accepted levels," said Darren Cook, director of...

Canadian study (VECTOR) presented at the 2009 American Urological Association Annual Meeting CHICAGO, April 30 /PRNewswire/ - Patients with overactive bladder (OAB) treated with solifenacin reported significantly lower incidence and severity of dry mouth, an often intolerable anti-cholinergic side effect, than those treated with oxybutynin immediate-release (IR). This was one of the key findings contained in the VECTOR (VEsicare in Comparison To Oxybutynin for oveRactive bladder...

BOTHELL, Wash., April 28 /PRNewswire/ -- Verathon(R) is pleased to announce the new BladderScan(R) BVM 9500 bladder volume instrument. Designed with Urologists in mind, the BVM 9500 measures both UEBW (ultrasound-estimated bladder weight) and bladder volume quickly and noninvasively to help diagnose bladder dysfunction, including BPH (benign prostatic hypertrophy) and BOO (bladder outlet obstruction). This new addition to the BladderScan(R) BVI 9000 series made its official debut at the...

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that data about the progress of Nymox's drug development for NX-1207, the Company's investigational drug for benign prostatic hyperplasia (BPH), were presented this morning at the 84th Annual Meeting of the Western Section of the American Urological Association being held in Monterey, CA. Barrett Cowan, MD, FACS, of Denver made the podium presentation. Dr. Cowan is an independent clinical investigator who has participated...

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company's latest multi-center U.S. study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH), is nearing completion. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks. The new study concerns assessment of the one year efficacy effects of a single treatment of NX-1207. NX-1207 has entered its Phase 3...

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) provided today an update on development activities for the Company's NX-1207 drug for the treatment of benign prostatic hyperplasia (BPH) or enlarged prostate, a common affliction of older men. The drug has the potential to have major impact on current management of BPH. Presentations of clinical study data at annual regional meetings of urologists in the U.S. in the last month were well-received and further presentations are scheduled in...

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce two separate presentations of new data by independent clinical investigators involved in U.S. clinical trials of NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The first presentation was at the annual meeting of the Northeastern Section of the American Urological Association in Santa Ana Pueblo, NM; the second at the annual meeting of the South Central Section of the American Urological...

By Ellsworth, Pamela Caldamone, Anthony Voiding dysfunction and urinary incontinence in children is common. Both are associated with significant effects on quality of life and comorbidities, including urinary tract infections (UTIs) and constipation. A thorough history, physical examination, and non- invasive evaluation are essential in determining the etiology. Interventions, such as behavioral therapy/biofeedback and pharmacologic therapies, are primary treatments. Prevalence rates,...

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that detailed new peer-reviewed data from the most recently completed clinical studies of NX-1207, the Company's drug in development for benign prostatic hyperplasia (BPH) will be presented at the Northeastern Section of the American Urological Association Meeting on September 18 in Santa Ana Pueblo, New Mexico. The Nymox investigational drug has entered Phase 3 development. NX-1207 is a novel drug developed by Nymox...

People using intermittent catheters no longer need to re-use their catheters due to a new Medicare policy effective April 1, 2008. The change affects nearly 1 million individuals living with spinal cord injury, multiple sclerosis and spina bifida, as well as those who have other permanent conditions requiring bladder management or experience urinary incontinence or retention. Backed by Coloplast Corp., members of Congress and the incontinence care community, the new policy eliminates...